Amgen is putting another $300 million into its Juncos biologics site in Puerto Rico, bringing total commitments at the site to nearly $1 billion and pushing the company’s U.S. manufacturing pledges to nearly $2 billion over the past year.
The Juncos plant, established in 1992, supplies biologics to more than 60 countries and is central to Amgen’s global production network. The additional capital keeps the original strategy intact: more biologics capacity, hundreds of new jobs. Amgen’s total U.S. outlay now runs alongside Novartis’s $23 billion domestic investment agenda as an industry benchmark for tariff-driven capital.
What does Amgen actually buy here? Production capacity at a site that already spans more than 20 buildings and employs thousands. Biologics can’t easily move offshore and back — it’s a manufacturing process measured in months, with validation cycles that don’t rush. Puerto Rico is a U.S. territory, so it counts as domestic for tariff purposes.
The tariff politics are inescapable. Amgen is one of 17 large pharma companies that signed “most favored nation” drug pricing deals with the White House, which also confer temporary relief from Trump’s proposed 100% import tariffs on certain patented drugs. The $300 million is consistent with that posture.
Beyond Juncos, Amgen’s capital plan includes a $900 million Ohio biomanufacturing expansion and a $600 million R&D center in Thousand Oaks, California. No timeline was given for the Juncos buildout’s completion.
Diana Kowalski